159 related articles for article (PubMed ID: 36358868)
1. CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy.
Turner E; Chen L; Foulke JG; Gu Z; Tian F
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358868
[No Abstract] [Full Text] [Related]
2. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
3. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Ohashi K; Sequist LV; Arcila ME; Moran T; Chmielecki J; Lin YL; Pan Y; Wang L; de Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; Yang JC; Miller VA; Riely GJ; Kris MG; Engelman JA; Vnencak-Jones CL; Dias-Santagata D; Ladanyi M; Pao W
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):E2127-33. PubMed ID: 22773810
[TBL] [Abstract][Full Text] [Related]
4. Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction.
Sale MJ; Balmanno K; Cook SJ
Cancer Drug Resist; 2019; 2(2):365-380. PubMed ID: 35582726
[TBL] [Abstract][Full Text] [Related]
5. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
6. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
Jaiswal BS; Janakiraman V; Kljavin NM; Eastham-Anderson J; Cupp JE; Liang Y; Davis DP; Hoeflich KP; Seshagiri S
PLoS One; 2009 May; 4(5):e5717. PubMed ID: 19492075
[TBL] [Abstract][Full Text] [Related]
7. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
[TBL] [Abstract][Full Text] [Related]
8. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
9. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
[TBL] [Abstract][Full Text] [Related]
10. Acquired Secondary RAS Mutation in BRAF
Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
[No Abstract] [Full Text] [Related]
11. Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status.
Calderon-Aparicio A; Cornejo A; Orue A; Rieber M
Ecancermedicalscience; 2019; 13():890. PubMed ID: 30792807
[TBL] [Abstract][Full Text] [Related]
12. Activating
Shirazi F; Jones RJ; Singh RK; Zou J; Kuiatse I; Berkova Z; Wang H; Lee HC; Hong S; Dick L; Chattopadhyay N; Orlowski RZ
Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20004-20014. PubMed ID: 32747568
[No Abstract] [Full Text] [Related]
13. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
Haagensen EJ; Thomas HD; Mudd C; Tsonou E; Wiggins CM; Maxwell RJ; Moore JD; Newell DR
Eur J Cancer; 2016 Mar; 56():69-76. PubMed ID: 26820797
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ
Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312
[TBL] [Abstract][Full Text] [Related]
15. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.
Shi H; Moriceau G; Kong X; Koya RC; Nazarian R; Pupo GM; Bacchiocchi A; Dahlman KB; Chmielowski B; Sosman JA; Halaban R; Kefford RF; Long GV; Ribas A; Lo RS
Cancer Discov; 2012 May; 2(5):414-24. PubMed ID: 22588879
[TBL] [Abstract][Full Text] [Related]
16. AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in
Flemington V; Davies EJ; Robinson D; Sandin LC; Delpuech O; Zhang P; Hanson L; Farrington P; Bell S; Falenta K; Gibbons FD; Lindsay N; Smith A; Wilson J; Roberts K; Tonge M; Hopcroft P; Willis SE; Roudier MP; Rooney C; Coker EA; Jaaks P; Garnett MJ; Fawell SE; Jones CD; Ward RA; Simpson I; Cosulich SC; Pease JE; Smith PD
Mol Cancer Ther; 2021 Feb; 20(2):238-249. PubMed ID: 33273059
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract][Full Text] [Related]
18. Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.
Stones CJ; Kim JE; Joseph WR; Leung E; Marshall ES; Finlay GJ; Shelling AN; Baguley BC
Front Genet; 2013; 4():66. PubMed ID: 23658559
[TBL] [Abstract][Full Text] [Related]
19. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
[TBL] [Abstract][Full Text] [Related]
20. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]